# Neratinib

## Nerlynx 40 mg (180 tablets/bot)

##### 臨採

| TAH Drug Code      | [ONER](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ONER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | NERLYNX as a monotherapy is indicated for the treatment of adult patients with early-stage HER2-positive breast cancer, as a post-trastuzumab-based adjuvant therapy for enhanced adjuvant treatment. NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 treatment regimens for metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Adjuvant treatment of HER2-positive early carcinoma of breast: As extended adjuvant treatment in patients who completed adjuvant trastuzumab-based therapy: 240 mg once daily, given continuously until disease recurrence or for up to 1 year. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. HER2-positive advanced carcinoma of breast, HER2-positive metastatic carcinoma of breast: In patients who have received > or = 2 prior anti-HER2 based regimens in the metastatic setting: 240 mg once daily on days 1-21 of a 21-day cycle; given with capecitabine on days 1-14 of a 21-day cycle, until disease progression or unacceptable toxicity. Antidiarrheal prophylaxis is recommended during the first 56 days of therapy; initiate with the 1st neratinib dose. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. Nerlynx Dose Modifications for Adverse Reactions (Dose Level and Nerlynx Dose): Recommended starting dose: 240 mg daily; First dose reduction: 200 mg daily; Second dose reduction: 160 mg daily; Third dose reduction: 120 mg daily. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Contraindications  | None.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common Dermatologic: Rash (18% ) Endocrine metabolic: Weight decreased (5% to 20% ) Gastrointestinal: Abdominal pain (36% ), Constipation (31% ), Decrease in appetite (12% to 35% ), Diarrhea (78% to 98% ), Indigestion (10% ), Nausea (43% to 53% ), Stomatitis (14% ), Vomiting (26% to 46% ) Hepatic: ALT/SGPT level raised (9% ), Aspartate aminotransferase serum level raised (7% ) Musculoskeletal: Spasm (11% ) Neurologic: Dizziness (14% ) Other: Fatigue (27% to 45% ) Serious Renal: Renal impairment (7% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/neratinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

